 YARDLEY, Pa., April 27, 2021 PRNewswire -- Optinose, NASDAQ: OPTN, a pharmaceutical company focused on patients treated by ear, nose and throat ENT and allergy specialists, today announced results of a new nationwide survey on chronic nasal congestion, its impact on daily activities, and awareness of nasal polyps as a possible cause. 